Lack of correlation between SREBF1 genotype and hyperlipidemia in individuals treated with highly active antiretroviral therapy

AIDS

Volumn 17, Issue 14, 2003, Pages 2142-2143

  Yang, Aiming ^a   King, Martin S ^a   Han, Lixin ^a   Isaacson, Jeffrey D ^a   Mueller, Toby ^a   Grimm, David R ^a   Brun, Scott C ^a   Katz, David A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN;

BODY REGIONS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LETTER; PRIORITY JOURNAL; RISK; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0142125245     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200309260-00024     Document Type: Letter

References (4)

1. Brown M, Goldstein J. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997, 89:331-340.
2. Miserez A, Muller P, Barella L, Schwietert M, Erb P, Vernazza P, et al. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS 2001, 15:2045-2049.
3. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002, 346:2039-2046.
4. Ioannidis J, Ntzani E, Trikalinos T, Contopoulos-Ioannidis D. Replication validity of genetic association studies. Nat Genet 2001, 29:306-309.